Search Results -

Term	Documents
(6 NOT 7).USPT.	136

Database: US Patents Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: l6 not l7 Clear

Search History

Today's Date: 7/19/2000

DB Name	Query	Hit Count	Set Name
USPT	l6 not l7	136	L8
USPT	l5 near10 l4	5	L7
USPT	l5 and l4	141	L6
USPT	antisense or anti-sense or anti sense	8819	L5
USPT	l1 or l2	3174	L4
USPT	nitricoxide synthase	0	L3
USPT	inos	2792	L2
USPT	nitric oxide synthase	474	L1

L7 Entry 2 of 5 File: USPT Nov 3, 1998

DOCUMENT-IDENTIFIER: US 5830848 A
TITLE: Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy

DEPR:
FIG. 14 is a photograph of in situ hybridization with a rat iNOS cDNA antisense probe for localization of iNOS expression in the pregnant rat uterus at day 16 (FIG. 14A); in the decidua basalis (FIG. 14B), in myocytes (FIGS. 14C and 14D).

DEPR:
The augmentation of uterine NO production is achieved by administration of agents enhancing the capacity of the uterus to make endogenous uterine NO. Such endogenous uterine NO production constituting endogenous tocolytic effect is achieved through administration of agents having a uterine-selective effect on iNOS in the myometrium. Such agents include systemically or by any other conventional route administered cytokines, growth factors, or sense or antisense oligonucleotides. Exemplary cytokines are Inf .gamma., IL-1.beta., IL-6, IL-8, TNF-.alpha., CSF-1, GM-CSF and TGF-.beta.. Exemplary growth factors are epidermal growth factor (EGF), fibroblast growth factors (FGFs), eicosanoids, alone or in combination with hormones such as progesterone or estradiol 17.beta., of which the levels are very high in pregnancy acting as an adjuvant. Exemplary sense or antisense oligonucleotides are antisense oligonucleotides directed against iNOS gene promoter repressor elements, or sense oligonucleotides directed towards iNOS gene promoter or promoters of genes for iNOS gene transcriptional regulators, which selectively increase uterine NO production. These agents are also delivered to the uterus in a targeted manner, for example, by complexing these agents with other biomolecules, such as hormones, antibodies, or nutrients, which are selectively taken up by or concentrated within the uterus or myometrium. Specific examples of these targeting techniques are complexing an agent with an oxytocin receptor antagonist, complexing an agent with an antibody directed to a uterine-specific antigen, and using liposomal carriers to deliver agents.

DEPR:
The all above discussed results of in vitro studies support the current invention and confirm results of in vivo studies which show that nitric oxide is directly involved in maintaining uterus relaxation during pregnancy. When the endogenous levels or availability of nitric oxide decrease, the uterus respond with increased contractility resulting in labor. When this occurs prior to normal term of pregnancy, such decreased level of nitric oxide results in preterm labor. By providing exogenous nitric oxide source or donor, the preterm contractions can be inhibited and the preterm labor stopped before resulting in preterm delivery. By providing agents hormones such as cytokines growth factors or sense or antisense oligonucleotides, the level of iNOS expression can be enhanced to prevent development or reverse onset of or stop premature labor.

DEPR:
For endogenous control of preterm labor through induction of increased production of NO by increased expression of iNOS, hormones, cytokines, growth factors, or sense or antisense oligonucleotides are administered in any suitable route described above.

McGarry, Sean

To: STIC-ILL
Subject: reference request

Importance: High

Please forward the following references to
Sean McGarry
AU 1635
CM1 11D07

L12 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2000 ACS
AN 1996:324381 CAPLUS
DN 125:54131
TI A first stable inducible ***nitric*** ***oxide*** ***synthase*** ***antisense*** macrophage cell line
AU Bosse, Geraldine; Fischer, Hans-Georg; Rothe, Helga
CS Diabetes Research Institute, Heinrich-Heine University, Duesseldorf, 40225, Germany
SO Portland Press Proc. (1996), 10(Biology of Nitric Oxide Part 5), 142
CODEN: POPPEF
DT Journal
LA English

L12 ANSWER 67 OF 79 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1996:255108 BIOSIS
DN PREV199698811237
TI Inducible ***nitric*** ***oxide*** ***synthase*** : The use of ***antisense*** oligodeoxynucleotides to study its regulation and role in neoplastic transformation.
AU Lesoon-Wood, L. A.; Lau, A. F.; Cooney, R. V.
CS Mol. Carcinogenesis, Cancer Res. Cent., Honolulu, HI 96813 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1996) Vol. 37, No. 0, pp. 145.
Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA April 20-24, 1996
ISSN: 0197-016X.
DT Conference
LA English

L12 ANSWER 61 OF 79 MEDLINE DUPLICATE 28
AN 97144252 MEDLINE
DN 97144252
TI Evidence for a physiological role for nitric oxide in the regulation of the LH surge: effect of central administration of ***antisense*** oligonucleotides to ***nitric*** ***oxide*** ***synthase*** .
AU Aguan K; Mahesh V B; Ping L; Bhat G; Brann D W
CS Department of Physiology and Endocrinology, Medical College of Georgia, [illegible]ugusta 30912-3000, USA
[illegible] ournal code: NY[illegible] ISSN 0028-38[illegible]
[illegible] Switzerland

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199706
EW 19970601

L12 ANSWER 60 OF 79 MEDLINE DUPLICATE 27
AN 96295522 MEDLINE
DN 96295522
TI ***Antisense*** evidence for two functionally active forms of ***nitric*** ***oxide*** ***synthase*** in brain microvascular endothelium.
AU Rosenblum W I; Murata S
CS Department of Pathology (Neuropathology), Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0017, USA.
NC HL35935 (NHLBI)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Jul 16) 224 (2) 535-43.
Journal code: 9Y8. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199611

L12 ANSWER 43 OF 79 MEDLINE DUPLICATE 19
AN 97368347 MEDLINE
DN 97368347
TI Functionally differentiating two neuronal ***nitric*** ***oxide*** ***synthase*** isoforms through ***antisense*** mapping: evidence for opposing NO actions on morphine analgesia and tolerance.
AU Kolesnikov Y A; Pan Y X; Babey A M; Jain S; Wilson R; Pasternak G W
CS The Cotzias Laboratory of Neuro-Oncology and Departments of Neurology and Anesthesiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
NC DA07242 (NIDA)
DA00220 (NIDA)
DA00296 (NIDA)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 Jul 22) 94 (15) 8220-5.
Journal code: PV3. ISSN: 0027-8424.

L12 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2000 ACS
AN 1997:168560 CAPLUS
DN 126:152830
TI Vascular endothelial growth factor receptor gene regulator screening, antisense and gene therapy, and cancer inhibitors, antiarteriosclerotics, and angiogenesis regulation
IN Patterson-Winston, Campbell; Lee, Mu-En; Haber, Edgar
PA President and Fellows of Harvard College, USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9700957 A1 19970109 WO 1996-US10725 19960621
W: AU, CA, IL, JP, MX, NO
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5888765 A 19990330 US 1995-494282 19950623
CA 2225460 AA 19970109 CA 1996-2225460 19960621
AU 9662884 A1 19970122 AU 1996-62884 19960621
EP 833907 A1 19980408 EP 1996-921746 19960621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 11509088 T2 19990817 JP 1996-503975 19960621
PRAI US 1995-494282 19950623
US 1995-573692 19951218
WO 1996-US10725 19960621